June 17, 2022
Another sector first from abdi ibrahim: sbti validates abdi ibrahim’s emission reduction targets
The Science Based Targets Initiative (SBTi) has validated the carbon emission reduction targets of Abdi İbrahim under the HEAL2030 strategy. Abdi İbrahim has thus become the first and only Turkish pharma company to have its commitments approved by the Science Based Targets Initiative (SBTi), to which it is signatory.
Following two years of intense work and stringent auditing processes, the Science Based Targets Initiative (SBTi) has approved the commitments made by Abdi İbrahim to reduce its carbon footprint under its HEAL2030 strategy. Accordingly, Abdi İbrahim has committed to achieve by 2030 a 60 percent reduction in the direct and indirect carbon emissions resulting from its operations, and a 45 percent reduction in all other indirect emissions arising from its supply chain and purchased products, in comparison to the 2020 reference year.
Bülbül: We are rapidly progressing toward our goal of carbon neutrality
Stating that Abdi İbrahim continues to progress in its sustainability efforts by the day, Abdi İbrahim Director of Corporate Relations, Sustainability and Communication Dr. M. Oğuzcan Bülbül said, “The increase in the global population, energy consumption, environmental pollution and social fractures, the natural disasters associated with the global warming that can be linked to the climate change caused by human activity, and the negative transformations being witnessed in nature are all issues that threaten our future. As Abdi İbrahim, we strive every day to help millions of people attain better, healthier and happier lives. We conduct projects with the leading universities of our country aimed at reducing the amount of packaging material used in our production processes, developing biodegradable polymers for our medicines and consumer health products, decreasing production waste and realizing a circular transformation of the linear structure of our industry, and allocate all the necessary resources to such projects. Recognizing our HEAL2030 sustainability strategy, through which we aim to generate more value for our stakeholders by using fewer resources, the Science Based Targets Initiative – to which we became signatory two years ago – has validated the commitments we have made under our sustainability strategy after a stringent auditing processes. We are thrilled to be the first Turkish pharma company to have its commitments validated by this prestigious initiative, which is followed closely by investors, public institutions and academic circles around the world.”
Bülbül stated out that the efficient use of resources and taking a responsible attitude toward nature are key considerations for Abdi İbrahim, adding: “As a company engaged in pioneering works in the domain of sustainability, we carry out our manufacturing operations at our Istanbul Esenyurt Production Complex under an International Renewable Energy Certificate (I-REC) – a first in the Turkish pharmaceutical sector – providing medicine and consumer health products manufactured entirely using renewable energy, to consumers in Turkey and in more than 60 countries around the world. Furthermore, we keep close track of progress in such key areas as Web 3.0, digitalization, the metaverse, machine learning, AI and wearable technologies, and the processing of the big data they provide, and engage in the production of customized consumer health products using 3D printers, taking significant steps in these domains. At the same time, we take well-earned pride in creating positive value for our sector, country and the world as we march towards our goal of becoming a carbon neutral company by 2030. We are continuing our pioneering works in the Turkish pharmaceutical sector in the fight against climate change, and strive to best manage the transition of our company to a low carbon economy under our HEAL2030 sustainability strategy with a view to gaining a significant competitive advantage both in our existing markets and in the markets we will enter in the coming years.”
The SBTi, a collaboration of the Carbon Disclosure Project (CDP), the United Nations Global Compact, the World Resources Institute (WRI) and the World Wildlife Fund (WWF), stands out as an initiative that encourages and independently evaluates companies in the setting of greenhouse gas emission reduction targets to meet the Paris Climate Agreement target of “keeping the global increase in temperature below 1.5°C”, and is actively participating in the fight against climate change using scientific calculations and data as the sole basis for the setting of sustainability commitments.
The SBTi has fifty-five pharma company signatories around the world, thirty-four of which have had their commitments confirmed. In Turkey, on the other hand, thirty-one companies have signed up to the SBTi (from all sectors). Abdi İbrahim became signatory to the SBTi two years ago and is the first and only Turkish pharma company among the seven companies from Turkey that have had their commitments confirmed to date.
